|
Synonyms: BOS 161721 | BOS161721
Compound class:
Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 [1].
|
Classification  |
|
| Compound class | Antibody |
| International Nonproprietary Names |
|
| INN number | INN |
| 11148 | avizakimab |
| Synonyms |
| BOS 161721 | BOS161721 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 941 |
| Other databases | |
| GtoPdb PubChem SID | 473153858 |
| Search PubMed clinical trials | avizakimab |
| Search PubMed titles | avizakimab |
| Search PubMed titles/abstracts | avizakimab |
